A phenylpropylamine is a phenethylamine homologue distinguished by a three-carbon propylamine side chain attached to a phenyl ring, in place of the two-carbon ethylamine chain of the parent scaffold.[1] The class is defined by this structural feature alone — chain length and topology — not by a shared receptor target or pharmacological outcome.
In practice the phenylpropylamines covered here are diphenylpropylamines — variants carrying a second phenyl group — and the members documented are methadone and dextropropoxyphene. The biaryl motif is the specific structural feature that lets this otherwise stimulant-adjacent scaffold engage opioid receptors instead, redirecting the family's pharmacology toward synthetic opioid analgesics.
The members produce a recognisably opioid clinical and subjective profile — analgesia, sedation, and CNS depression deepening with exposure — and have been used as prescription analgesics and, in methadone's case, as a long-acting medication for opioid use disorder.[1] At higher exposures the class converges on opioid-typical respiratory depression, compounded by cardiac conduction effects arising from the diphenylpropylamine scaffold itself.
Pharmacology
Across the members covered here the phenylpropylamine scaffold converges, via its diphenylpropylamine variant, on full mu-opioid receptor (MOR) agonism as the shared pharmacological action.[1]
| Mechanism | Representative members | How it reaches the shared endpoint |
|---|---|---|
| Mu-opioid receptor agonism | methadone, dextropropoxyphene | Inhibits adenylyl cyclase and modulates K+/Ca2+ channel conductance, suppressing neuronal excitability to produce analgesia and CNS depression[1] |
| hERG potassium channel inhibition | methadone | Blocks the cardiac repolarising K+ current, prolonging the QTc interval and raising torsades de pointes risk[2] |
| Cardiac Na+ channel blockade | dextropropoxyphene | Slows the fast-sodium conduction system, widening QRS and prolonging PR even at therapeutic doses[3] |
| NMDA receptor antagonism | methadone | Blocks glutamatergic central sensitisation, contributing to neuropathic-pain activity and potentially moderating tolerance to its own analgesia[1] |
The molecular detail that distinguishes the members matters less for the shared safety endpoint than the convergence itself: MOR agonism at the brainstem dose-dependently suppresses respiratory drive, and that effect is additive with other CNS depressants. Layered on top is a second class-distinguishing endpoint — cardiac arrhythmia risk — reached by two different routes (hERG blockade in one member, sodium channel blockade in the other) but expressed as overlapping conduction-system hazard.
Substances
The class as defined by the brief is small and is illustrated by two diphenylpropylamine opioids whose clinical trajectories diverged sharply:
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| Methadone | Diphenylpropylamine | Long-acting full MOR agonist with secondary NMDA antagonism; used clinically for moderate-to-severe pain and as a maintenance medication for opioid use disorder[1] |
| Dextropropoxyphene | Diphenylpropylamine | Mild-to-moderate analgesic prescribed widely from the 1960s; progressively withdrawn from major markets between 2005 and 2010 over cardiac safety and overdose toxicity[3] |
These two members differ in half-life, clinical role, and current availability, but both contribute opioid depressant load and both carry a cardiac conduction risk that is unusual among opioid subclasses.
Subjective Effects
Across the class the subjective trajectory tracks the opioid axis as exposure rises.[1]
| Exposure | Characteristic effects |
|---|---|
| Low | Analgesia (pain felt as emotionally distant rather than absent), mild sedation, anxiolysis, a warm mood shift, pupil constriction, and mild nausea |
| Moderate–high | Deepening sedation, cognitive slowing, slurred speech, impaired coordination, slowed respiratory rate, and euphoria that can shade into dysphoria or nausea |
| High | Marked CNS depression, impaired consciousness, dose-dependent suppression of respiratory drive, and — for this subclass specifically — compounding cardiac arrhythmia risk at high plasma concentrations |
The same MOR-driven axis that produces the desired analgesia and mood shift also produces the respiratory depression that defines opioid overdose, and the margin between heavy sedation and life-threatening depression narrows as exposure rises. The diphenylpropylamine scaffold adds a second compounding hazard: cardiac conduction effects whose risk also rises with plasma concentration, so the high-exposure endpoint stacks respiratory and cardiac danger together rather than either alone.
Safety
Risk profile
The defining acute danger of this class is opioid-type respiratory depression compounded by cardiac arrhythmia. At high plasma concentrations both members suppress brainstem respiratory drive while simultaneously prolonging cardiac conduction intervals — methadone through hERG channel blockade and dextropropoxyphene through cardiac sodium channel blockade. Stacking another CNS depressant on top sharply raises the risk of fatal overdose.[1][3]
Methadone-associated QTc prolongation is dose-related and is worsened by polypharmacy with other QTc-prolonging agents, electrolyte disturbance, hepatic impairment, and CYP3A4 or CYP2D6 inhibitors that raise methadone plasma concentrations.[2] Dextropropoxyphene's sodium channel blockade produced QT prolongation, PR prolongation, and QRS widening even at recommended therapeutic doses.[3]
That profile, combined with a narrow therapeutic index, drove regulatory withdrawal across the United Kingdom, the European Union, and the United States between 2005 and 2010, and was associated with elevated overdose toxicity mortality in epidemiological data.[4]
As MOR agonists the members interact additively with other CNS depressants — alcohol, benzodiazepines, other opioids, and sedating medications — to compound respiratory depression. Naloxone reverses opioid-driven respiratory depression but does not reverse the cardiac conduction effects, which require separate emergency management.
Tolerance & dependence
Regular use of either member produces tolerance through MOR desensitisation, internalisation, and compensatory upregulation of adenylyl cyclase signalling, with cross-tolerance across the wider opioid class.[5] Methadone's NMDA antagonism may moderate tolerance accumulation to its own analgesic effect, which is part of why it is useful in long-term pain management and maintenance treatment.[1]
Physical dependence is an expected pharmacological consequence of sustained MOR agonism rather than a marker of compulsive use.[5] Withdrawal presents as a cluster of autonomic-hyperactivity symptoms — elevated heart rate and blood pressure, sweating, piloerection, rhinorrhoea, lacrimation, mydriasis, muscle pain, gastrointestinal cramping, nausea, vomiting, diarrhoea, insomnia, anxiety, and intense craving.[6]
Unlike alcohol or benzodiazepine withdrawal, opioid withdrawal in otherwise healthy adults is not typically directly lethal. It does, however, carry a serious indirect risk: tolerance falls quickly during abstinence while substance availability does not, so relapse after a withdrawal episode is associated with a sharply elevated risk of fatal overdose. Methadone's long half-life delays the onset of withdrawal and produces a more protracted but lower-intensity syndrome than short-acting opioids.[1]
Recovery
Opioid dependence is treatable. Medication for opioid use disorder — typically methadone or buprenorphine — is associated with better treatment retention and lower relapse than detoxification alone, and is the standard of care for sustained recovery.[7] Acute withdrawal is managed with medically supervised tapering, alpha-2 agonists for autonomic symptoms, and adjunct antiemetics and antidiarrhoeals.[6] If you or someone you know is dependent on an opioid, a clinician or an opioid treatment programme can structure a safe transition.Recovery resources, crisis lines, and support pathways → View all
Sub-classes
Members
references
- [1]
- [2]^abPani, P.P. and Trogu, E. and Maremmani, I. and Pacini, M. (2013) QTc interval screening for cardiac risk in methadone treatment of opioid dependence — Cochrane Database of Systematic Reviews doi:10.1002/14651858.cd008939.pub2
- [3]
- [4]^Ray WA, Murray KT, Kawai V, Graham DJ, Cooper WO, Hall K, Stein CM (2013) Propoxyphene and the risk of out-of-hospital death — Pharmacoepidemiology and Drug Safety doi:10.1002/pds.3411
- [5]^abAdriaensen, H. and Vissers, K. and Noorduin, H. and Meert, T. (2003) Opioid tolerance and dependence: an inevitable consequence of chronic treatment? — Acta Anaesthesiologica Belgica PMID:12703345
- [6]